🎧 The GLP-1 Business Model Problem, Ep. 1 with Prof. Alex Miras

The episode opens with a deep dive into the emerging oral GLP‑1 market, highlighted by the recent launch of oral Wegovy. Professor Alex Miras emphasizes that oral tablets provide a valuable alternative for patients averse to injections, yet he warns that price will be the decisive factor in widespread adoption. While the fasting‑required dosing regimen adds a modest barrier, the convenience of a daily pill could attract a segment of the obesity‑treatment population, especially where injectable costs remain prohibitive.

Miras contrasts the modest efficacy of oral agents—averaging roughly 12% weight loss—with the 20%+ results seen from weekly injectables. He introduces the concept of “super‑responders,” patients who exceed average outcomes, and notes the current inability to predict who will fall into this group. Real‑world tolerability also diverges from trial data; tirzepatide, for example, is generating more nausea in practice, prompting clinicians to adopt slower titration schedules. These nuances suggest that beyond price, tolerability and patient preference will shape long‑term adherence.

Looking ahead, Miras projects a continued dominance of injectables, estimating a 60‑70% market share over the next five years, with oral formulations capturing the remaining 30‑40% if priced competitively. He stresses that successful obesity management will hinge on personalized care—matching drug choice to individual cost sensitivity, side‑effect tolerance, and lifestyle habits. While biomarkers for response or gastrointestinal risk remain elusive, incremental improvements in dosing strategies and broader drug classes may gradually refine patient segmentation, positioning GLP‑1 therapies as a cornerstone of chronic obesity treatment.